[HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM.

about

[HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM.

Item

http://www.wikidata.org/entity/Q48331580

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

[HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM.

@en

[HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM.

@nl

type

Item

label

[HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM.

@en

[HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM.

@nl

prefLabel

[HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM.

@en

[HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM.

@nl

P1476

[HDL-C/apoA-I]: A multivessel cardiometabolic risk marker in women with T2DM.

@en

P2093

Michel F Rousseau

http://www.w3.org/2001/XMLSchema#string

Paul Valensi

http://www.w3.org/2001/XMLSchema#string

Sylvie A Ahn

http://www.w3.org/2001/XMLSchema#string

P2860

High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk

Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes

Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus.

The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females.

Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.

A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study.

Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids.

High-density lipoproteins: a consensus statement from the National Lipid Association.

P31

scholarly article

P356

10.1002/DMRR.2950

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michel P Hermans

P577

2017-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28921828

http://www.w3.org/2001/XMLSchema#string